2352792
Last Update Posted: 2015-02-02
Recruiting status is unknown
All Genders accepted | 18 Years + |
90 Estimated Participants | No Expanded Access |
Interventional Study | Does not accept healthy volunteers |
Hypoxia-based Dose Escalation With Radiochemotherapy in Head and Neck Cancer
Patients with locally advanced suqamous cell carcinoma of the head and neck region receive a hypoxia scan either by magnetic resonance tomography, computed tomography or fluoromisonidazole (FMISO)-PET-CT. Patients presenting with hypoxia are randomized into standard therapy consisting of intensity modulated radiotherapy (IMRT) with 70 Gy plus either 5-fluorouracil/mitomycin C or cisplatinum (Arm A) or a dose escalation of 10% (77Gy) to the hypoxic volume applied via simultaneous integrated boost in addition to the standard treatment (Arm B).
Eligibility
Relevant conditions:
Squamous Cell Carcinoma of the Head and Neck
If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the trial if you think are close to fitting criteria.
locations
Data sourced from ClinicalTrials.gov